We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hutchmed (china) Limited | LSE:HCM | London | Ordinary Share | KYG4672N1198 | ORD USD0.10 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 14.00 | 5.07% | 290.00 | 290.00 | 292.00 | 295.00 | 275.00 | 275.00 | 262,868 | 16:29:57 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 838M | 100.78M | - | N/A | 0 |
From Apr 2019 to Apr 2024
LONDON--Hutchison China Meditech Ltd. (HCM.LN) said Monday that it has submitted a new drug application to China Food and Drug Administration for cancer treatment drug fruquintinib.
The pharmaceutical company added that the submission has triggered a milestone payment of 30.8 million Chinese yuan ($4.5 million) from Lilly (LLY).
Hutchison China Meditech is majority owned by CK Hutchison Holdings Ltd (0001.HK).
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
June 12, 2017 02:42 ET (06:42 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Hutchmed (china) Chart |
1 Month Hutchmed (china) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
